Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;11(6):1199-1216.
doi: 10.1007/s13300-020-00816-y. Epub 2020 Apr 15.

Drug Therapy in Obesity: A Review of Current and Emerging Treatments

David M Williams  1 , Asif Nawaz  2 , Marc Evans  2
Affiliations
Review

Drug Therapy in Obesity: A Review of Current and Emerging Treatments

David M Williams et al. Diabetes Ther. 2020 Jun.

Abstract

Whilst the prevalence of obesity continues to increase at an alarming rate worldwide, the personal and economic burden of obesity-related complications becomes ever more important. Whilst dietary and lifestyle measures remain the fundamental focus of the patient to counter obesity, more frequently pharmacological and/or surgical interventions are required. Nevertheless, these therapies are often limited by weight loss efficacy, side effects, surgical risks and frequently obesity relapse. Currently, only five drug therapies are approved for the specific treatment of obesity. However, our understanding of the pathophysiology of obesity and of gut hormones has developed precipitously over the last 20-30 years. As a result, there has been a recent movement to create and use analogues that manipulate these gut hormones to support weight loss. In this article we review the efficacy of the currently approved drug therapies and discuss future potential drug mechanisms and early clinical trial results exploring these budding avenues. We discuss the use of glucagon-like peptide-1 (GLP-1) analogues as monotherapy and unimolecular dual or triple agonists that exploit the GLP-1 receptor and/or the gastric inhibitory peptide (GIP) receptor and/or the glucagon receptor. We also explore the use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, amylin mimetics, leptin analogues, ghrelin antagonists and centrally acting agents to suppress appetite [neuropeptide Y (NPY) antagonists, melanocortin-4 receptor (MC4R) agonists and cannabinoid-1 receptor antagonists]. Whilst further evidence is required to support their clinical use, preclinical and early clinical trial results are encouraging.

Keywords: Amylin mimetics; GIP agonist; GLP-1 analogue; Ghrelin antagonists; Glucagon receptor agonist; Leptin analogues; Obesity; SGLT-2 inhibitor.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Summarises the mechanism of action for each class of pharmacotherapy used to treat obesity
See this image and copyright information in PMC

References

    1. Purnell JQ. Definitions, classification, and epidemiology of obesity. 2018. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. https://www.ncbi.nlm.nih.gov/books/NBK279167/. Accessed 31 Mar 2020
    1. UK Parliament. House of Commons Library: Obesity Statistics. 2019. https://researchbriefings.parliament.uk/ResearchBriefing/Summary/SN03336. Accessed 23 Feb 2020.
    1. World Health Organization (WHO). Obesity and Overweight. 2018. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 23 Feb 2020.
    1. Cawley J, Meyerhoefer C. The medical care costs of obesity: an instrumental variables approach. J Health Econ. 2012;31(1):219–230. - PubMed
    1. Public Health England. Health matters: obesity and the food environment. 2017. https://www.gov.uk/government/publications/health-matters-obesity-and-th.... Accessed 23 Feb 2020.